Skip directly to content

By Suraj Madoori

During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S.

By Erica Lessem

The road from Moscow has led us back to New York, home of the United Nations (UN) and TAG headquarters. New York is also home to one of the largest tuberculosis (TB) burdens in the U.S.[1] Incidence in New York City rose in 2017, and multidrug-resistant TB (MDR-TB), which is costly and difficult to diagnose and treat, is also on the rise.[2] Despite growing needs, funding for the TB response in New York City has dropped steadily over the past ten years, and fell precipitously in 2017 when New York State issued a surprise cut to its main TB budget line.

By Safiqa Khimani and Mark Harrington

Global political will to combat tuberculosis (TB)—once again the world’s leading killer infectious disease—may be increasing as shown by intensified activities leading to the upcoming United Nations (UN) High-Level Meeting (HLM) on Tuberculosis in September 2018.

The build-up to the HLM included the Global Ministerial Conference on Ending Tuberculosis in the Sustainable Development Era—held in Moscow, Russian Federation, in November 2017—which endorsed the World Health Organization’s (WHO) End TB Strategy targets, an 80 percent decrease in the number of

By Bryn Gay & Annette Gaudino

Are we on track with WHO targets[1,2] to eliminate the hepatitis C virus (HCV) by 2030? Andrew Hill, Senior Research Fellow, Liverpool University unveils powerful research that compares 91 countries’ data on HCV prevalence, diagnosis, treatment, and income level. One central concern is that annually treating an estimated 1.42 million (2%)[3] people with diagnosed HCV infection—especially those with healthcare coverage—is insufficient given the enormity of the epidemic.

By Annette Gaudino

Governor Andrew Cuomo’s March 16 announcement committing New York State (NYS) to ending the hepatitis C virus (HCV) epidemic was the culmination of years of advocacy on a path that paralleled—and is built upon—the state’s nation leading efforts to end the HIV epidemic.

The HCV burden in NYS, and in the U.S., is high and is growing, with the concurrent opioid epidemic driving a 290% increase in the number of new cases between 2010 and 2015.[1] In NYS this translates into 14,745 new HCV infections in 2016,[2] as compared with 2,881 new HIV cases in the same year.[3]

Prior to

By Richard Jefferys

The development of highly effective approaches to HIV treatment and prevention—in the form of combination antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP)—stands among the most impressive scientific achievements in human history. As detailed elsewhere in this issue of TAGline, the widespread implementation of these interventions has the potential, at least theoretically, to effectively end the HIV pandemic.

By Jeremiah Johnson

The December 2017 release of the New York State (NYS) 2016 HIV/AIDS surveillance data shows that the efforts to End the Epidemic (EtE) in New York are having an impact.

In 2014, Governor Andrew Cuomo backed a community-developed plan to aggressively scale up testing, linkage to care and treatment, and pre-exposure prophylaxis access to dramatically reduce new infections below epidemic levels by the year 2020. Numerically speaking, the number of new infections would decrease from approximately 3,000 annually to fewer than 750 a year, effectively “bending the curve” on

By Jeremiah Johnson

Since 2014, several states, cities, and counties have announced plans to End the Epidemic (EtE), with many more preparing to announce their own initiatives in 2018. In New York, early successes have emerged in the most recent surveillance data (see: “New York State EtE Campaign Update: Successes & Challenges,” and several other jurisdictions are seeing the benefits of EtE plan implementation. However, a number of common challenges have become apparent across different jurisdictions.

By Tim Horn

Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.
                                                                      — Desmond Mpilo Tutu

Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible. But in the context of public health strategies with ambitious targets and formidable stakeholder engagement, it is an undeniable facet of progress. In this issue of TAGline, we

August 23, 2018 – Treatment Action Group seeks a dynamic intern to support the hepatitis C virus program. This is an unpaid internship position and would be suitable to serve as course credit.

Treatment Action Group’s Hepatitis C Virus Project reviews the state of research on HCV monoinfection and coinfection. It advocates for better clinical trial designs, access to curative treatment for all affected communities, and it continually monitors standards of care for people with HCV monoinfection and coinfection.